WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
- PMID: 29360529
- DOI: 10.1016/j.juro.2017.12.065
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
Abstract
Purpose: We compared the safety and efficacy of Aquablation and transurethral prostate resection for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Materials and methods: In a double-blind, multicenter, prospective, randomized, controlled trial 181 patients with moderate to severe lower urinary tract symptoms related to benign prostatic hyperplasia underwent transurethral prostate resection or Aquablation. The primary efficacy end point was the reduction in International Prostate Symptom Score at 6 months. The primary safety end point was the development of Clavien-Dindo persistent grade 1, or 2 or higher operative complications.
Results: Mean total operative time was similar for Aquablation and transurethral prostate resection (33 vs 36 minutes, p = 0.2752) but resection time was lower for Aquablation (4 vs 27 minutes, p <0.0001). At month 6 patients treated with Aquablation and transurethral prostate resection experienced large I-PSS improvements. The prespecified study noninferiority hypothesis was satisfied (p <0.0001). Of the patients who underwent Aquablation and transurethral prostate resection 26% and 42%, respectively, experienced a primary safety end point, which met the study primary noninferiority safety hypothesis and subsequently demonstrated superiority (p = 0.0149). Among sexually active men the rate of anejaculation was lower in those treated with Aquablation (10% vs 36%, p = 0.0003).
Conclusions: Surgical prostate resection using Aquablation showed noninferior symptom relief compared to transurethral prostate resection but with a lower risk of sexual dysfunction. Larger prostates (50 to 80 ml) demonstrated a more pronounced superior safety and efficacy benefit. Longer term followup would help assess the clinical value of Aquablation.
Keywords: lower urinary tract symptoms; prostatic hyperplasia; robotic surgical procedures; transurethral resection of prostate; water.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia.Eur Urol. 2018 Aug;74(2):233. doi: 10.1016/j.eururo.2018.03.026. Epub 2018 Apr 9. Eur Urol. 2018. PMID: 29650236 No abstract available.
Similar articles
-
Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial.BJU Int. 2019 Apr;123(4):651-660. doi: 10.1111/bju.14426. Epub 2018 Jul 26. BJU Int. 2019. PMID: 29862630 Clinical Trial.
-
Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes.Can J Urol. 2018 Jun;25(3):9317-9322. Can J Urol. 2018. PMID: 29900819 Clinical Trial.
-
Aquablation versus TURP: 5-year outcomes of the WATER randomized clinical trial for prostate volumes 50-80 mL.Can J Urol. 2023 Oct;30(5):11650-11658. Can J Urol. 2023. PMID: 37838991 Clinical Trial.
-
Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Cochrane Database Syst Rev. 2019 Feb 13;2(2):CD013143. doi: 10.1002/14651858.CD013143.pub2. Cochrane Database Syst Rev. 2019. PMID: 30759311 Free PMC article.
-
Will Aquablation Be the New Benchmark for Robotic Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia?Eur Urol Focus. 2024 Jul;10(4):581-593. doi: 10.1016/j.euf.2023.12.001. Epub 2023 Dec 29. Eur Urol Focus. 2024. PMID: 38160171 Review.
Cited by
-
[Novel minimally invasive treatment options for male lower urinary tract symptom].Urologe A. 2019 Mar;58(3):254-262. doi: 10.1007/s00120-019-0876-7. Urologe A. 2019. PMID: 30790004 Review. German.
-
CUA 2022 Annual Meeting Abstracts - Podium Session 1: BPH, GU Trauma and Reconstruction, Neurogenic Bladder, Urinary Incontinence and Voiding Dysfunction, Pediatrics Friday, June 24, 2022 • 13:30-14:30.Can Urol Assoc J. 2022 Jun;16(6 Suppl 1):S5-S7. doi: 10.5489/cuaj.7919. Can Urol Assoc J. 2022. PMID: 35667349 Free PMC article. No abstract available.
-
Contemporary practice patterns of transurethral therapies for benign prostate hypertrophy: results of a worldwide survey.World J Urol. 2021 Nov;39(11):4207-4213. doi: 10.1007/s00345-021-03760-z. Epub 2021 Jun 18. World J Urol. 2021. PMID: 34143283
-
Six novel minimally invasive therapies for benign prostatic hyperplasia.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Apr 25;52(2):162-168. doi: 10.3724/zdxbyxb-2022-0593. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37283100 Free PMC article. Chinese, English.
-
UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.Can Urol Assoc J. 2022 Aug;16(8):245-256. doi: 10.5489/cuaj.7906. Can Urol Assoc J. 2022. PMID: 35905485 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous